The safety of treatment options for pediatric Crohn's disease

Area of Science:

• Pediatric gastroenterology
• Inflammatory bowel disease research
• Clinical pharmacology

Background:

• Pediatric Crohn's disease (CD) diagnosis necessitates careful treatment selection due to severe phenotypes and growth concerns.
• Conventional therapies include aminosalicylates, corticosteroids, and immunomodulators, particularly for high-risk pediatric CD patients.

Purpose of the Study:

• To review the efficacy and safety of conventional and emerging therapies for pediatric Crohn's disease.
• To evaluate the long-term implications of current treatment strategies on disease progression and patient outcomes.

Main Methods:

• Literature review of studies on pediatric Crohn's disease treatment.
• Analysis of safety and efficacy data for aminosalicylates, corticosteroids, immunomodulators, anti-TNF-α agents, and anti-adhesion therapies.
• Assessment of risks including malignancy, lymphoma, and hemophagocytic lymphohistiocytosis.

Main Results:

• Aminosalicylates show minimal supporting data for pediatric CD treatment.
• Corticosteroids offer short-term symptom relief but lack maintenance efficacy.
• Thiopurines reduce corticosteroid dependence but may not prevent disease progression or surgery, with associated risks.
• Anti-TNF-α therapy is generally well-tolerated but carries potential complications; no increased malignancy risk noted with anti-TNF therapy alone.
• Anti-adhesion therapy shows a favorable safety profile, but pediatric data are limited.

Conclusions:

• Current conventional therapies for pediatric Crohn's disease have significant limitations in efficacy and safety.
• Biologic therapies like anti-TNF-α agents offer alternatives but require ongoing safety monitoring.
• Further research is needed on methotrexate and anti-adhesion therapies in pediatric CD.